TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07254585: An Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of SYS6010 Combined With Immunotherapy in the Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 110 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07254585 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07254585 Rescue Dossier →